// App-Quantinova.ai

1826 : Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study

Researchers

Presenter

  • Laura C Coates

Principal Investigators

  • Dafna D Gladman

  • Peter Nash

  • Oliver Fitz Gerald

  • Arthur Kavanaugh

  • Lawrence Rasouliyan

  • Luminita Pricop

  • Kevin Ding

  • Corine Gaillez

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Toronto Western Hospital, Toronto, ON, Canada

  • The University of Queensland, Brisbane, Australia

  • St Vincent's University Hospital, Dublin, Ireland

  • UCSD School of Medicine, La Jolla, CA

  • RTI Health Solutions, Barcelona, Spain

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

Locations

  • United Kingdom

  • Canada

  • Australia

  • Ireland

  • United States

  • Spain

  • Switzerland

Companies

  • RTI Health Solutions

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved